Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Han Yang, Nan Li, Youlian Zhou, Zhilan Xiao, Haoming Tian, Ming Hu & Sheyu Li. (2020) Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis. Drug Design, Development and Therapy 14, pages 157-165.
Read now
Read now
Jesse D. Ortendahl, Amanda L. Harmon, Tanya G. K. Bentley & Michael S. Broder. (2017) A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. Journal of Medical Economics 20:7, pages 767-775.
Read now
Read now
Nazik Elmalaika Husain, Abdallah Tarig Hassan, Wadie M Elmadhoun & Mohamed H Ahmed. (2015) Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?. Expert Opinion on Drug Safety 14:9, pages 1445-1455.
Read now
Read now
Articles from other publishers (7)
Diana Tavares, Helena Mouriño, Cristina Antón Rodríguez & Carlos Martín Saborido. (2022) Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population. Vaccines 10:8, pages 1285.
Crossref
Crossref
Akhil Sasidharan, Bhavani Shankara Bagepally, S. Sajith Kumar, Kayala Venkata Jagadeesh & Meenakumari Natarajan. (2022) Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. PLOS ONE 17:6, pages e0264563.
Crossref
Crossref
Dina Abushanab, Daoud Al-Badriyeh, Clara Marquina, Cate Bailey, Myriam Jaam, Danny Liew & Zanfina Ademi. (2022) A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Current Problems in Cardiology, pages 101211.
Crossref
Crossref
D. Boyers, L. Retat, E. Jacobsen, A. Avenell, P. Aveyard, E. Corbould, A. Jaccard, D. Cooper, C. Robertson, M. Aceves-Martins, B. Xu, Z. Skea, M. de Bruin, E. Jacobsen, D. Boyers, D. Cooper, L. Retat, P. Aveyard, Fiona Stewart, Graeme MacLennan, Laura Webber, E. Corbould, B. Xu, A. Jaccard, Bonnie Boyle, Eilidh Duncan, Michal Shimonovich, Cynthia Fraser & Lara Kemp. (2021) Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model. International Journal of Obesity 45:10, pages 2179-2190.
Crossref
Crossref
Lise Retat, Laura Pimpin, Laura Webber, Abbygail Jaccard, Amanda Lewis, Sarah Tearne, Kathryn Hood, Anna Christian-Brown, Peymane Adab, Rachna Begh, Kate Jolly, Amanda Daley, Amanda Farley, Deborah Lycett, Alecia Nickless, Ly-Mee Yu, Susan Jebb & Paul Aveyard. (2019) Screening and brief intervention for obesity in primary care: cost-effectiveness analysis in the BWeL trial. International Journal of Obesity 43:10, pages 2066-2075.
Crossref
Crossref
Gang Ma & Shuting Bi. (2018) Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease. Experimental and Therapeutic Medicine.
Crossref
Crossref
Alison Avenell, Clare Robertson, Zoë Skea, Elisabet Jacobsen, Dwayne Boyers, David Cooper, Magaly Aceves-Martins, Lise Retat, Cynthia Fraser, Paul Aveyard, Fiona Stewart, Graeme MacLennan, Laura Webber, Emily Corbould, Benshuai Xu, Abbygail Jaccard, Bonnie Boyle, Eilidh Duncan, Michal Shimonovich & Marijn de Bruin. (2018) Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation. Health Technology Assessment 22:68, pages 1-246.
Crossref
Crossref